“The observed data showed all three pre-specified performance goals were met. These data suggest a lower rate of rescue therapy than prior thrombectomy trials and may demonstrate that intracranial positioning of a super-large bore catheter...
“The observed data showed all three pre-specified performance goals were met. These data suggest a lower rate of rescue therapy than prior thrombectomy trials and may demonstrate that intracranial positioning of a super-large bore catheter...
LINC, the world’s premier interdisciplinary live course for vascular and endovascular teams, announced that its annual meeting is shifting from summer to winter, with its 20th anniversary Congress in January 2025.
LINC, the world’s premier interdisciplinary live course for vascular and endovascular teams, announced that its annual meeting is shifting from summer to winter, with its 20th anniversary Congress in January 2025.
Based on physician feedback, the new Zoom 6F Insert Catheters were developed to be more supportive, more torque-able and longer than current vessel selection devices and are offered in three stroke-specific shapes.
Based on physician feedback, the new Zoom 6F Insert Catheters were developed to be more supportive, more torque-able and longer than current vessel selection devices and are offered in three stroke-specific shapes.
“The XO technology has shown effectiveness modifying, cracking, and dilating intimal and medial calcium using low pressures,” said Richard Saxon, MD, FSIR of Tri-City Medical, San Diego, California.
“The XO technology has shown effectiveness modifying, cracking, and dilating intimal and medial calcium using low pressures,” said Richard Saxon, MD, FSIR of Tri-City Medical, San Diego, California.
Transit Scientific Press Release
Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular
procedures, proudly announces the successful debut of XO...
Transit Scientific Press Release
Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular
procedures, proudly announces the successful debut of XO...
Leveraging GRIP TECHNOLOGY™, based on hydrophilic, bioinert polyethylene glycol (PEG), the MYNX CONTROL™ VENOUS VCD sealant resorbs 3x faster than collagen-based sealants and provides the quickest time to hemostasis of any venous closure...
Leveraging GRIP TECHNOLOGY™, based on hydrophilic, bioinert polyethylene glycol (PEG), the MYNX CONTROL™ VENOUS VCD sealant resorbs 3x faster than collagen-based sealants and provides the quickest time to hemostasis of any venous closure...
ZACHARY, LA – Dr. Abdullah Munir, interventional cardiologist at Cardiovascular Institute of the South (CIS), is the first in the Capital Region and second in Louisiana to use the AGENT™ Drug-Coated Balloon, the first FDA-approved drug-coated...
ZACHARY, LA – Dr. Abdullah Munir, interventional cardiologist at Cardiovascular Institute of the South (CIS), is the first in the Capital Region and second in Louisiana to use the AGENT™ Drug-Coated Balloon, the first FDA-approved drug-coated...
The first flexible, off-the-shelf single-branch thoracic endoprosthesis for zone 2 treatment.
FLAGSTAFF, AZ (June 27, 2024) — W. L. Gore & Associates (Gore) today announced the first commercial use of the GORE® TAG® Thoracic Branch...
The first flexible, off-the-shelf single-branch thoracic endoprosthesis for zone 2 treatment.
FLAGSTAFF, AZ (June 27, 2024) — W. L. Gore & Associates (Gore) today announced the first commercial use of the GORE® TAG® Thoracic Branch...
Innovative Health, Inc. and US Endovascular announced that they have entered into an agreement that will enable US Endovascular’s partners among ambulatory surgery centers (ASCs) and office-based labs (OBLs) to benefit from the rapidly...
Innovative Health, Inc. and US Endovascular announced that they have entered into an agreement that will enable US Endovascular’s partners among ambulatory surgery centers (ASCs) and office-based labs (OBLs) to benefit from the rapidly...
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD)
Cardiovascular...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD)
Cardiovascular...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System
LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System
LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness
Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness
Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...